Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2015

Tiseo Marcello, Bersanelli Melissa, Perrone Federica, Tamborini Elena, Settanni Giulio, Busico Adele, Rossi Giulio, Ardizzoni Andrea, Pelosi Giuseppe

Abstract excerpt

We present a very interesting case of lung adenocarcinoma carrying an uncommon EGFR exon 19 insertion with concomitant PIK3CA mutation showing dramatic and persisting improvement upon erlotinib therapy, after progression during PI3K inhibitor.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Immunohistochemistry

Share to Nuclear Proteins

Share to Protein Kinase Inhibitors

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 25555368
DOI: 10.1016/j.lungcan.2014.12.008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.PMID 25555368Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.Semantic proximity Read ↗

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs.Semantic proximity Read ↗

A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.Semantic proximity Read ↗

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.Semantic proximity Read ↗

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.Semantic proximity Read ↗

An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.Semantic proximity Read ↗

Different EGFR gene mutations in two patients with synchronous multiple lung cancers: A case report.Semantic proximity Read ↗

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.Semantic proximity Read ↗

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.Semantic proximity Read ↗

A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.Semantic proximity Read ↗

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.